Please find attached
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
India Glycols delivered strong FY26 performance with Net Revenue of ₹4,211 Cr (+11.8% YoY), EBITDA of ₹654 Cr (+24.5% YoY), and PAT of ₹293 Cr (+26.8% YoY). Q4FY26 also showed robust growth with PAT up 35.7% YoY. Finance costs declined sharply to ₹26 Cr in Q4FY26 from ₹45 Cr in Q4FY25 due to debt reduction via preferential allotment and internal accruals. Cash generation from operations surged to ₹769 Cr, up 112.4% YoY. The company proposed a major restructuring to demerge into three separate listed entities: IGL (chemicals), IGL Spirits (spirits & bio-fuel), and Ennature Bio Pharma (biopharma). NCLT has admitted the demerger scheme with next hearing on May 21, 2026.
Strong operational performance with margin expansion (EBITDA margin up 162 bps to 15.5%) and significant debt reduction position the company well. The proposed demerger could unlock value by creating focused businesses. Shareholders will receive shares in all three entities post-restructuring with promoters holding 59.63% in each.